Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-08

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Teva Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for levothyroxine sodium from Teva Pharmaceuticals under ANDA 207588. This represents a routine update to an existin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)